


We claim:

1. The compound of formula I and the pharmaceutically acceptable salts and tautomers thereof:

5



wherein:

R¹ is -C₁₋₆alkyl;

R² is -phenyl, unsubstituted, mono- or polysubstituted with a substituent

10 selected from the group consisting of -halo, -C₁₋₆alkyl, -CF₃, -O-C₁₋₆alkyl, and
-NO₂;

R³ is selected from the group consisting of -H and -C₁₋₆alkyl;

R⁴ is -C₁₋₆alkyl;

R⁵ is -C₁₋₆alkyl;

15 R⁶ is each independently selected from the group consisting of: -halo,

-C₁₋₆alkyl, -CF₃, -O-C₁₋₆alkyl, and -NO₂; and

q is an integer from 0 to 4.

2. The compound of claim 1 and the pharmaceutically acceptable salts and tautomers

20 thereof, wherein R¹ is -methyl.

3. The compound of claim 2 and the pharmaceutically acceptable salts and tautomers

thereof, wherein R² is -phenyl, unsubstituted, mono- or polysubstituted with a substituent selected from the group consisting of: -halo, -C₁₋₆alkyl, -CF₃, and -O-C₁₋₆alkyl.

25

4. The compound of claim 3 and the pharmaceutically acceptable salts and tautomers

thereof, wherein R² is selected from the group consisting of: -3-chlorophenyl, -4-

chlorophenyl, -4-methoxyphenyl, -3-trifluoromethyl-phenyl, -4-trifluoromethyl-phenyl, -

3,4-dichlorophenyl, -3-bromophenyl, -4-bromophenyl and -3-trifluoromethyl-4-chlorophenyl.

5. The compound of claim 3 and the pharmaceutically acceptable salts and tautomers thereof, wherein R³ is -H.
6. The compound of claim 4 and the pharmaceutically acceptable salts and tautomers thereof, wherein R³ is -H.
- 10 7. The compound of claim 5 and the pharmaceutically acceptable salts and tautomers thereof, wherein R⁴ is -CH₃.
8. The compound of claim 6 and the pharmaceutically acceptable salts and tautomers thereof, wherein R⁴ is -CH₃.
- 15 9. The compound of claim 7 and the pharmaceutically acceptable salts and tautomers thereof, wherein R⁵ is -CH₃.
10. The compound of claim 8 and the pharmaceutically acceptable salts and tautomers thereof, wherein R⁵ is -CH₃.
- 20 11. The compound of claim 9 and the pharmaceutically acceptable salts and tautomers thereof, wherein R⁶ is selected from the group consisting of -CH₃ and -halo.
- 25 12. The compound of claim 10 and the pharmaceutically acceptable salts and tautomers thereof, wherein R⁶ is selected from the group consisting of -CH₃ and -halo.
13. The compound of claim 11 and the pharmaceutically acceptable salts and tautomers thereof, wherein q is 0 to 2.

14. The compound of claim 12 and the pharmaceutically acceptable salts and tautomers thereof, wherein q is 0 to 2.


15. The compound of claim 1, wherein said compound is selected from the group

5 consisting of:

- (1) Methyl-{1-[2-(1-phenyl-ethyl)-phenyl]-ethyl}-amine,
- (2) Methyl-{1-[2-(1-phenyl-propyl)-phenyl]-ethyl}-amine,
- (3) Dimethyl-{1-[2-(1-phenyl-ethyl)-phenyl]-ethyl}-amine,
- (4) Methyl-{1-[2-(1-phenyl-ethyl)-phenyl]-propyl}-amine,
- 10 (5) (1-{2-[1-(3,4-Dichloro-phenyl)-ethyl]-phenyl}-ethyl)-methyl-amine,
- (6) {1-[4,5-Dimethyl-2-(1-phenyl-ethyl)-phenyl]-ethyl}-methyl-amine,
- (7) {1-[4,5-Dichloro-2-(1-phenyl-ethyl)-phenyl]-ethyl}-methyl-amine,
- (8) (1-{2-[1-(4-Chloro-phenyl)-ethyl]-phenyl}-ethyl)-methyl-amine,
- (9) (1-{2-[1-(3-Chloro-phenyl)-ethyl]-phenyl}-ethyl)-methyl-amine,
- 15 (10) (1-{2-[1-(4-Methoxy-phenyl)-ethyl]-phenyl}-ethyl)-methyl-amine,
- (11) Methyl-(1-{2-[1-(4-trifluoromethyl-phenyl)-ethyl]-phenyl}-ethyl)-amine,
- (12) Methyl-(1-{2-[1-(3-trifluoromethyl-phenyl)-ethyl]-phenyl}-ethyl)-amine,
- (13) (1-{2-[1-(3,4-Dichloro-phenyl)-ethyl]-phenyl}-ethyl)-methyl-amine,
- (14) (1-{2-[1-(4-Bromo-phenyl)-ethyl]-phenyl}-ethyl)-methyl-amine,
- 20 (15) (1-{2-[1-(3-Bromo-phenyl)-ethyl]-phenyl}-ethyl)-methyl-amine, and
- (16) (1-{2-[1-(4-Bromo-3-trifluoromethyl-phenyl)-ethyl]-phenyl}-ethyl)-methyl
amine,

and pharmaceutically acceptable salts and tautomers thereof.

25 16. A pharmaceutical composition comprising a pharmaceutically acceptable carrier and as active ingredient the compound of formula I and pharmaceutically acceptable salts and tautomers thereof:



wherein:

R¹ is -C₁₋₆alkyl;

R² is -phenyl, unsubstituted, mono- or polysubstituted with a substituent selected from the group consisting of -halo, -C₁₋₆alkyl, -CF₃, -O-C₁₋₆alkyl, and -NO₂;

R³ is selected from the group consisting of -H and -C₁₋₆alkyl;

R⁴ is -C₁₋₆alkyl;

R⁵ is -C₁₋₆alkyl;

R⁶ is each independently selected from the group consisting of: -halo, -C₁₋₆alkyl, -CF₃, -O-C₁₋₆alkyl, and -NO₂; and

q is an integer from 0 to 4.

10

17. A method of treating depression in a patient, which method comprises administering to a patient a therapeutically effective amount of the compound of claim 1.

18. The method of claim 17, wherein said depression is selected from the group consisting of: unipolar depression, dysthymia, bipolar depression, treatment-resistant depression, and depression in the medically-ill.

20